Innocoll to Report Third Quarter 2016 Financial Results and Host Webcast and Conference Call on November 22, 2016
November 15 2016 - 8:30AM
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty
pharmaceutical company with late stage development programs
targeting areas of significant unmet medical need, today announced
that it will report third quarter financial results before the open
of U.S. financial markets on November 22, 2016. Innocoll management
will host a webcast and conference call at 8:30 a.m. ET that day to
discuss the financial results and provide a corporate update.
Interested parties may access the live webcast
and call through the Investors section of the company website at
www.innocoll.com or directly through the registration link. A
recording will be archived on the company website for 90 days.
The live call may be accessed by dialing
877-407-9039 for domestic callers and 201-689-8470 for
international callers. A telephone replay of the call will be
available until 11:59 p.m. ET on November 29, 2016 by dialing
877-870-5176 for domestic callers or 858-384-5517 for international
callers and entering the conference code: 48285346.
About Innocoll Holdings PLC
Innocoll is a global, commercial-stage,
specialty pharmaceutical company that is dedicated to engineering
better medicines to help patients get better. Our proprietary,
biocompatible, and biodegradable collagen products are
precision-engineered for targeted use. Applied locally to surgery
sites, they are designed to provide a range of benefits. The
company's late stage product pipeline is focused on addressing a
number of large unmet medical needs, including: XARACOLL® for the
treatment of postoperative pain and COLLAGUARD (INL-003), a barrier
for the prevention of post-surgical adhesions.
Our currently approved products include:
COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E,
REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are
sold globally through strategic partnerships, including those with
Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native
collagen products — from extraction/purification of type-1 collagen
through final delivery form — are manufactured at our certified,
integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com.
CollaRx®, Collatamp®, COLLAGUARD®, Collieva®, CollaCare®, Collexa®,
COGENZIA® LidoColl®, LiquiColl®, and XARACOLL® are registered
trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are
trademarks of the company.
Contact:
Pepe Carmona
Chief Financial Officer
(215) 983-3362
pcarmona@innocoll.com
Jeannie Sorenson, M.D.
Vice President, Investor Relations
(314) 458-7355
jsorenson@innocoll.com
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Apr 2023 to Apr 2024